LM2010_banner-logo

 

Welcome to the HCV Advocate’s 2010 AASLD Conference coverage.  In an effort to best serve our readership, we are concentrating on the current and future medications to treat hepatitis C.  While attending the conference, we will update any abstracts that we personally cover at the conference. The updated abstracts will be marked with the date that they have been updated and posted.  The other abstracts posted to the web site are HCV-related abstracts posted to www.aasld.org that we have not been able to report on or update.  

 

To locate specific abstracts for each medication, click on the links.

 

Please click here to view our fact sheet on reading and understanding an abstract.

 

 

Thank You,

Alan Franciscus

Editor-in-Chief

 

 

Hepatitis C

 

 

 

·        Interferon and Ribavirin Therapy – New Studies: The current treatments for hepatitis C, including outcomes, side effects and treatment of various HCV populations. 

 

·        Direct-Acting Antiviral Agents (DAA’s):  New treatments for hepatitis C that have been studied in humans, and various drugs that are in phase I, II and III development to treat hepatitis C.

 

·        Miscellaneous Studies:

 

·        Post-Conference Highlights: